(BAX) Baxter International - Ratings and Ratios

Baxter International Inc. (NYSE:BAX) is a global leader in healthcare products and services, operating through four distinct segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The companys extensive portfolio includes sterile IV solutions, infusion systems, parenteral nutrition therapies, generic injectable pharmaceuticals, surgical hemostat and sealant products, and advanced surgical equipment. Additionally, Baxter offers smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. Their surgical space equipment encompasses surgical video technologies, precision positioning devices, and other accessories.

Baxter also provides administrative sets, adhesion prevention products, inhaled anesthesia, drug compounding, and chronic and acute dialysis therapies. These include peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The companys products are utilized across various healthcare settings, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors offices, and home care under physician supervision. Baxter distributes its products through a direct sales force and independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries.

Baxter has strategic collaborations, such as an agreement with Celerity Pharmaceutical, LLC, to develop acute care generic injectable premix and oncolytic products. They also have a research partnership with Miromatrix Medical Inc. to advance care for patients with acute liver failure. Incorporated in 1931, Baxter is headquartered in Deerfield, Illinois, and is a well-established player in the healthcare industry.

From a financial perspective, Baxter has a market capitalization of $15.634 billion USD. The companys trailing P/E ratio is 122.48, with a forward P/E of 12.76, indicating expectations of future growth. The price-to-book (P/B) ratio is 1.99, and the price-to-sales (P/S) ratio is 1.04. These metrics provide insight into the companys valuation and potential for investors.

Baxters diverse product portfolio, global reach, and strategic partnerships position it as a critical player in the healthcare equipment industry. For investors and fund managers, Baxters financial metrics and market position offer a balanced view of its stability and potential growth opportunities.